Patients with endometrial cancer found to be dMMR by IHC should be referred for MLH1 gene promoter hypermethylation (in case of MLH1/PMS2 loss) and/or germline testing regardless of results of MSI testing by molecular methods. Here, MLH1 is linked to endometrial cancer.